← Back to home

FDA Rejects Summit's Lung Cancer Drug Ivonescimab Over Survival Data

Fact checked by NewsPlainVerified by NewsPlain: confirmed by at least two named sources

Brief

Summit Therapeutics said Nov. 15 that it had received a complete response letter from the FDA, meaning its request to sell ivonescimab cannot be approved…

Keep reading with NewsPlain Premium

Get the full brief, the full story, what's confirmed, what's still unclear, why it matters, and every source.

4 confirmed facts, 1 open question and 2 sources behind this story.

About this story

We haven’t published a correction to this story.

How NewsPlain works
← Back to home